Livagen (20mg)

Livagen Peptide

Livagen is a short peptide bioregulator, similar in structure to Epitalon. It is a tetrapeptide made of the amino acids Lys-Glu-Asp-Ala (KEDA) and is classified amongst Khavinson’s peptides. As a bioregulator, the peptide may interact with genetic material in different cells and consequently unpack and “unlock” various cellular genes. Livagen’s impacts appear to be exhibited directly on the lymphocytes (cells of the immune system), liver, and gastrointestinal tract (GIT). Its direct functions may be widespread, as suggested through research studies on DNA and gene expression patterns. The potential of the Livagen peptide to activate genes enclosed in the GIT and immune system may reflect possible age-mitigating characteristics exerted on cells.

Specifications

Sequence Formula: Lys-Glu-Asp-Ala

Molecular Formula: C₁₈H₃₁N₅O₉

Molecular Weight: 461.5g/mol

Synonyms: SCHEMBL5967826

Livagen Research

Livagen Peptide and Chromatin

In eukaryotes, the cell nucleus houses DNA, with chromatin representing the ensemble of genomic DNA and associated proteins that condense to form chromosomes.[1] This organizational structure is understood to encapsulate genetic material for cell division and replication, enable genetic material to fit within cells, and regulate gene expression at a macroscopic level. Livagen may influence certain cellular activities in lymphocytes — white blood cells considered essential to immune function. Specifically, it may affect the activity of nucleolar organizer regions (NORs), segments of chromosomal DNA believed to be essential for ribosomal RNA synthesis and nucleolus formation within the cell nucleus. Some studies suggest that Livagen may alter NOR activity and potentially modify the frequency with which acrocentric chromosomes associate in lymphocytes. Acrocentric chromosomes are characterized by a centromere positioned near one end, producing one very short arm and one long arm, with associations among these chromosomes potentially playing a role in genetic regulation and overall cellular function. Such changes may arise from the decondensation of heterochromatin — a tightly packed form of chromatin — potentially activating previously silenced genes and supporting improvements in cellular function.

Livagen Peptide and Immune Cells

Research has suggested that Livagen may activate several genes in lymphocytes through potential chromatin unpacking.[2] This may allow previously silent genes to become active, indirectly activating ribosomal genes involved in protein production and elevated cellular activity.[3] According to this research, Livagen appears to exert four distinct potential actions on lymphocytes: gene expression alteration, decondensation activity, ribosomal gene activation, and chromatin unpacking. Scientists have proposed that prolonged Livagen exposure in older animal research models may alter lymphocyte expression profiles to more closely resemble those observed in younger counterparts.

Lymphocytes — encompassing both T and B cells — are considered fundamental to immune system function. B cells are understood to serve as primary producers of antibodies against foreign and invasive cellular structures, while T cells produce cytokines and participate in the destruction of cancerous or infected cells. The proposed capacity of Livagen to rejuvenate these immunologically significant cells may contribute to an extended functional lifespan.

Livagen Peptide and Cell Aging

Certain consequences of cellular aging may stem from changes in DNA organization, including alterations in the genes expressed and accessible within a cell. Research by Professor Teimuraz Lezhava has reported that the degree of chromosomal aberrations may increase over time.[4] Chromatin condensation and diminished DNA repair processes represent examples of such chromosomal irregularities. According to this research, Livagen and a select group of other bioregulator peptides may potentially enhance DNA decondensation and consequently contribute to an extension of cell viability under experimental conditions.[5]

Livagen Peptide and Heart Cells

Livagen is proposed to interact with various tissues indirectly through its influence on gene expression in immune cells, which in turn modulates inflammation across a range of models. One such example involves cardiac cells, whose function is closely regulated by inflammatory and immune activity. Research in models of hypertrophic cardiomyopathy (HCM) suggests that dysregulation of chromatin structure in lymphocytes may be pathogenic in HCM and that addressing this may improve long-term outcomes.[6]

By potentially influencing chromatin structure and gene expression, Livagen may interact with cardiac cells in ways that support their functionality. Researchers noted that “Livagen (characterized by modifying influence on chromatin) separately and in combination with cobalt ions, [appears to promote] normalization of altered genomic indicators of atherosclerosis.” The research further suggests that releasing genes through decondensed chromatin in lymphocytes may reduce the long-term consequences of cardiac disease.[7] Researchers propose that Livagen may hold potential to facilitate such a reduction, though investigation is ongoing. Alterations in lymphocyte gene expression appear to be associated with decreased inflammation and reduced scarring in HCM models.

Livagen and the Gastrointestinal System

Early research has proposed that activated delta cells may protect the mucosal wall of the gastrointestinal tract (GIT). Building on this, the Livagen peptide appears to enhance vagus nerve signaling to the GIT and may potentially modulate prostaglandin and nitric oxide levels within the mucosa.[8] Gastroprotective effects may additionally be generated, potentially establishing a pathway for Livagen in research related to chronic conditions such as diarrhea, inflammatory bowel disease, and broader GIT dysfunction.

Livagen and Pain Signaling

Enkephalin is an endogenous peptide recognized for its dynamic influence on pain perception, appearing to bind to delta and mu-opioid receptors. Activated mu receptors may bind to compounds such as morphine to reduce pain perception and blood pressure, while activated delta receptors may attenuate pain signaling to the brain and may partly account for respiratory depression sometimes associated with opiate exposure. Research suggests that Livagen may inhibit the enzymatic degradation of enkephalin in the blood, resulting in elevated endogenous painkiller levels.[9] To investigate this, researchers studied labeled enkephalin molecules (3H-Leu-enkephalin) and measured the rate of their degradation with and without Livagen introduction. The peptide significantly slowed the breakdown of the labeled enkephalin molecule. Further research suggested that Livagen may influence enkephalin levels exclusively through inhibition of their degradation, without appearing to bind to or directly affect opioid receptors in the brain.

Livagen and Antioxidant Systems in Liver Cells

Livagen has been studied for its potential antioxidative properties in in vitro models of liver pathology. In experiments simulating liver fibrosis and hepatitis, Livagen appeared to demonstrate efficacy in normalizing antioxidant status.[10] The peptide may help restore liver function under conditions of hepatic stress, and may exert hepatoprotective and immunoprotective effects — properties that could be particularly relevant in the context of cellular aging, where oxidative stress is a recognized contributing factor. These findings suggest that Livagen

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References

1. van Steensel B. (2011). Chromatin: constructing the big picture. The EMBO journal, 30(10), 1885–1895. https://doi.org/10.1038/emboj.2011.135
2. Khavinson, V. K.h, Lezhava, T. A., Monaselidze, J. G., Dzhokhadze, T. A., Dvalishvili, N. A., Bablishvili, N. K., & Ryadnova, I. Y. (2002). Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bulletin of experimental biology and medicine, 134(4), 389–392. https://doi.org/10.1023/a:1021924702103
3. Lezhava, T., Monaselidze, J., Kadotani, T., Dvalishvili, N., & Buadze, T. (2006). Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian medical news, (133), 111–115.
4. Lezhava T. A. (2001). Funktsional’nye osobennosti khromosom cheloveka i starenie [Human chromosome functional characteristics and aging]. Advances in gerontology = Uspekhi gerontologii, 8, 34–43.
5. Khavinson, V. K.h, Lezhava, T. A., Monaselidze, J. R., Jokhadze, T. A., Dvalishvili, N. A., Bablishvili, N. K., & Trofimova, S. V. (2003). Peptide Epitalon activates chromatin at the old age. Neuro endocrinology letters, 24(5), 329–333.
6. Dzhokhadze, T. A., Buadze, T. Z.h, Gaiozishvili, M. N., Kakauridze, N. G., & Lezhava, T. A. (2014). Georgian medical news, (236), 82–86.
7. Lezhava, T., & Jokhadze, T. (2007). Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. Annals of the New York Academy of Sciences, 1100, 387–399. https://doi.org/10.1196/annals.1395.043
8. Gyires, K., & Rónai, A. Z. (2001). Supraspinal delta- and mu-opioid receptors mediate gastric mucosal protection in the rat. The Journal of pharmacology and experimental therapeutics, 297(3), 1010–1015.
9. Kost, N. V., Sokolov, O. I.u, Gabaeva, M. V., Zolotarev, I.uA., Malinin, V. V., & Khavinson, V. K.h (2003). Vliianie novykh peptidnykh bioreguliatorov livagena i épitalona na énkefalindegradiruiushchie fermenty syvorotki krovi cheloveka [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. Izvestiia Akademii nauk. Seriia biologicheskaia, (4), 427–429.
10. Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK. [The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.]. Adv Gerontol. 2020;33(1):159-164. Russian. PMID: 32362099.